Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.

Autor: Gregersen, Henrik1 (AUTHOR) henrik.gregersen@rn.dk, Peceliunas, Valdas2 (AUTHOR), Remes, Kari3 (AUTHOR), Schjesvold, Fredrik4,5 (AUTHOR), Abildgaard, Niels6,7 (AUTHOR), Nahi, Hareth8 (AUTHOR), Andersen, Niels Frost9 (AUTHOR), Vangsted, Annette Juul10 (AUTHOR), Klausen, Tobias Wirenfeldt11 (AUTHOR), Helleberg, Carsten11 (AUTHOR), Carlson, Kristina12 (AUTHOR), Frølund, Ulf Christian13 (AUTHOR), Axelsson, Per14 (AUTHOR), Stromberg, Olga8 (AUTHOR), Blimark, Cecilie Hveding15 (AUTHOR), Crafoord, Jacob16 (AUTHOR), Tsykunova, Galina17 (AUTHOR), Eshoj, Henrik Rode18,19 (AUTHOR), Waage, Anders20 (AUTHOR), Hansson, Markus21 (AUTHOR)
Zdroj: European Journal of Haematology. Jan2022, Vol. 108 Issue 1, p34-44. 11p.
Databáze: Academic Search Ultimate